



# Cutaneous Lupus (CLE) Clinical Trials

Principle Investigator: Dr. Werth

CLE Subtype

Discoid  
(DLE)

Subacute or Chronic  
(SCLE or CCLE)

Current drug trials

Phase 2 RCT:  
**Daxdilimab** (anti pDC/IFN-1)

Phase 2/3 RCT:  
**Litifilimab** (anti pDC/IFN-1)

Randomization design

\*placebo crossover to treatment arm after 24 weeks

1:1:1  
Placebo\* vs. 150 mg vs. 300 mg  
SC injection Q4W

1:2  
Placebo\* vs. Litifilimab  
SC injection Q4W

Inclusion criteria

Diagnosis of DLE  $\geq$  6 months  
CLASI-A  $\geq$  8  
Treatment refractory

Diagnosis of CLE with or without SLE  
CLASI-A  $\geq$  10  
Antimalarial  $\geq$  12 weeks (cumulative)

Exclusion criteria

Diagnosis of SLE  
Systemic CTD

Other systemic autoimmune disease  
(except Sjogrens)  
Severe lupus nephritis  
Active neuropsychiatric SLE

If your patient may be eligible, email [penndermautoimmune@pennmedicine.upenn.edu](mailto:penndermautoimmune@pennmedicine.upenn.edu) for a screening appointment with Dr. Werth